Ryvu Therapeutics S.A.
RVU.WA
Price:
$14.44
Market Cap:
$333.85M
Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing novel small molecule treatments for oncology. Their primary experimental drug, RVU120, functions as a CDK8 kinase inhibitor and shows promise for development across hematological malignancies and solid tumors. This compound is presently in a Phase 1b clinical study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Among their other assets is SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, which is currently undergoing a Phase 2 clinical trial for acute myeloid leukemia. Furthermore, Ryvu's earlier research pipeline explores candidate...[Read more]
Industry
Biotechnology
IPO Date
2011-07-14
Stock Exchange
WSE
Ticker
RVU.WA
PE Ratio
[-3.80]
ROE
[-135.46%]
Current Ratio
[2.26]
Dividend Yield
[0%]
Enterprise Value
[361.85M]
Dividend History
The ROE as of June 2026 (TTM) for Ryvu Therapeutics S.A. (RVU.WA) is -135.46%
According to Ryvu Therapeutics S.A.’s latest financial reports and current stock price. The company's current ROE is -135.46%. This represents a change of 306.47% compared to the average of -33.33% of the last 4 quarters.
Ryvu Therapeutics S.A. (RVU.WA) Historical ROE (quarterly & annually)
How has RVU.WA ROE performed in the past?
The mean historical ROE of Ryvu Therapeutics S.A. over the last ten years is -40.35%. The current -135.46% ROE has changed 235.74% with respect to the historical average. Over the past ten years (40 quarters), RVU.WA's ROE was at its highest in in the March 2018 quarter at 9.42%. The ROE was at its lowest in in the June 2025 quarter at -35.34%.
Average
-40.35%
Median
-27.23%
Minimum
-188.04%
Maximum
10.28%
Ryvu Therapeutics S.A. (RVU.WA) ROE by Quarter and Year
Discovering the peaks and valleys of Ryvu Therapeutics S.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 54.16%
Maximum Annual ROE = 10.28%
Minimum Annual Increase = -100.54%
Minimum Annual ROE = -188.04%
| Year | ROE | Change |
|---|---|---|
| 2025 | -188.04% | 142.79% |
| 2024 | -77.45% | 118.27% |
| 2023 | -35.48% | 45.43% |
| 2022 | -24.40% | -50.23% |
| 2021 | -49.02% | 246.13% |
| 2020 | -14.16% | -52.88% |
| 2019 | -30.06% | 54.16% |
| 2018 | -0.06% | -100.54% |
| 2017 | 10.28% | 109.36% |
| 2016 | 4.91% | -63.61% |
Ryvu Therapeutics S.A. (RVU.WA) Average ROE
How has RVU.WA ROE performed in the past?
The current ROE of Ryvu Therapeutics S.A. (RVU.WA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-100.32%
5-year avg
-74.88%
10-year avg
-40.35%
Ryvu Therapeutics S.A. (RVU.WA) ROE vs. Peers
How is RVU.WA’s ROE compared to its peers?
Ryvu Therapeutics S.A.’s ROE is greater than Bioceltix S.A. (-34.50%), greater than Captor Therapeutics Spolka Akcyjna (-150.18%), less than Selvita S.A. (-1.15%), greater than Molecure S.A. (-15.59%), less than Bioton S.a. (0.69%), greater than Poltreg S.A. (-59.09%), less than Centrum Medyczne ENEL-MED S.A. (4.21%), greater than Scope Fluidics S.A. (-35.29%), greater than Mabion S.A. (-95.68%), greater than Synthaverse S.A. (-18.68%),
| Company | ROE | Market cap |
|---|---|---|
| -34.50% | $492.37M | |
| -150.18% | $485.14M | |
| -1.15% | $567.07M | |
| -15.59% | $113.32M | |
| 0.69% | $340.88M | |
| -59.09% | $86.74M | |
| 4.21% | $537.33M | |
| -35.29% | $336.38M | |
| -95.68% | $124.45M | |
| -18.68% | $204.58M |
Build a custom stock screener for Ryvu Therapeutics S.A. (RVU.WA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ryvu Therapeutics S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Ryvu Therapeutics S.A. (RVU.WA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Ryvu Therapeutics S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Ryvu Therapeutics S.A.'s ROE?
How is the ROE calculated for Ryvu Therapeutics S.A. (RVU.WA)?
What is the highest ROE for Ryvu Therapeutics S.A. (RVU.WA)?
What is the 3-year average ROE for Ryvu Therapeutics S.A. (RVU.WA)?
What is the 5-year average ROE for Ryvu Therapeutics S.A. (RVU.WA)?
How does the current ROE for Ryvu Therapeutics S.A. (RVU.WA) compare to its historical average?